MS-based approaches for studying the pharmacokinetics of protein drugs

“[MS-based quantitative assays] offer interesting characteristics in terms of specificity, precision and robustness, transferability and multiplexing ability ... MS utilization could overcome antidrug antibodies interference and deal with questions of metabolism.” The development of new therapeutic proteins and peptides currently involves over 200 companies, sharing a strong growth market of €90 billion in 2010 (vs €25 billion in 2001) [1]. Over 700 therapeutic antibodies, proteins and peptides entered clinical trials between 1980 and 2004, representing half of all medications in the development phase in 2008 [2]. This increasing number of protein drugs highlights the need for the development of quantitative...